William Blair analyst Raju Prasad initiated coverage with a Buy rating on Celyad (NASDAQ: CYAD) today. The company’s shares closed yesterday at $24.45, close to its 52-week low of $22.17.
Prasad said:
“Celyad S.A. Using the Body’s “Natural Born Killers” in Solid and Liquid Tumors; Initiating With an Outperform Rating We are initiating coverage on Celyad with an Outperform rating and $53 fair value estimate.”
According to TipRanks.com, Prasad has 0 stars on 0-5 star ranking scale with an average return of -7.3% and a 21.7% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Audentes Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Celyad with a $46 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $59.05 and a one-year low of $22.17. Currently, Celyad has an average volume of 7,926.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celyad SA is a clinical-stage biopharmaceutical company, which engages in the identification and development of specialized cell-based therapies. Its products include cardiopoiesis platform, immuno-oncology, and medical devices. The company was founded by Michel Lussier and William Wijns on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.